Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials.
Source: FierceBiotech
You may also like
Cancer, immune drugmakers dominate VC funding so far...
Beyond Boston: Unlikely cities stake biotech claims
Vera Therapeutics wins FDA nod for closely watched...
Gene editing developer Scribe plots an IPO
Novartis to acquire ADC developer in a deal worth up...
Novartis to pay $1.1B upfront for UK biotech Myricx to...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.